Study weighs point-of-care biomarkers for Doberman DCM screening
Bottom line
Version 1
A newly accepted Frontiers in Veterinary Science study suggests that in-clinic Vcheck V200 assays for NT-proBNP and cardiac troponin I can help identify dilated cardiomyopathy in Doberman Pinschers, but they don't appear to match the diagnostic performance of a laboratory-based IDEXX cardiac troponin I assay, especially for earlier-stage disease. The prospective longitudinal study, by Helena Driessen, Jana Friederich, and Gerhard Wess, was listed by Frontiers as accepted on July 31, 2026. It evaluates point-of-care biomarker testing against established screening approaches in a breed with a high lifetime burden of DCM, where echocardiography and ambulatory ECG remain the reference standards. (frontiersin.org)
Why it matters: For veterinarians, the takeaway is practical rather than disruptive. Biomarker testing may support screening conversations, triage, and follow-up when advanced cardiac testing isn't immediately available, but it shouldn't be treated as a replacement for echo and Holter monitoring in Dobermans. That matters because prior literature and breed-screening guidance already frame NT-proBNP and cTnI as useful adjuncts, while emphasizing that annual screening and confirmatory testing are still needed in this high-risk population. (pubmed.ncbi.nlm.nih.gov)
What to watch: Watch for the full Frontiers publication, including sensitivity, specificity, and cutoff data that could clarify where Vcheck fits in real-world screening workflows. (frontiersin.org)
Key facts
- Study type
- Prospective longitudinal study
- Breed
- Doberman Pinschers
- Condition
- Dilated cardiomyopathy
- Point-of-care assays
- Vcheck V200 NT-proBNP and cardiac troponin I
- Comparator
- Laboratory-based IDEXX cardiac troponin I assay
- Main finding
- Vcheck assays helped identify dilated cardiomyopathy, but did not match the lab-based IDEXX cTnI assay, especially for earlier-stage disease
- Accepted
- July 31, 2026
- Authors
- Helena Driessen, Jana Friederich, and Gerhard Wess
A forthcoming Frontiers in Veterinary Science paper adds new evidence on a familiar clinical question in Doberman cardiology: how far point-of-care biomarkers can go in detecting dilated cardiomyopathy before a patient reaches advanced testing. According to the study summary, Vcheck V200 NT-proBNP and cardiac troponin I assays offered practical in-clinic assessment, but a laboratory-based IDEXX cTnI assay performed better overall, particularly for detecting earlier-stage disease. Frontiers lists the paper, by Helena Driessen, Jana Friederich, and Gerhard Wess, as accepted on July 31, 2026. (frontiersin.org)
That finding lands in a breed where screening strategy already matters a great deal. European Society of Veterinary Cardiology guidance describes Doberman DCM as a common inherited disease with high prevalence, and recommends yearly screening throughout life because a single normal screen doesn't rule out future disease. Those guidelines also position biomarkers, including NT-proBNP and troponin I, as useful screening tools, but not substitutes for echocardiography and rhythm assessment. (pubmed.ncbi.nlm.nih.gov)
The new study builds on a substantial biomarker literature in Dobermans. Earlier work found NT-proBNP and troponin I can help detect occult disease and provide prognostic information, including associations with shorter survival and sudden cardiac death risk. More recent studies have also shown that cardiac biomarkers can perform reasonably well for screening, while still leaving gold-standard imaging and Holter monitoring as the basis for diagnosis. (pubmed.ncbi.nlm.nih.gov)
What appears new here is the focus on the Vcheck V200 platform in a prospective longitudinal design, and the direct comparison with an IDEXX laboratory cTnI assay. Independent analytical validation of the canine Vcheck NT-proBNP assay has been published previously, supporting the platform's technical feasibility, but analytical validity doesn't automatically translate into best-in-class clinical discrimination in a disease-screening setting. Based on the study abstract provided and Frontiers' listing, this paper suggests that distinction matters in Doberman DCM, especially if the clinical goal is catching disease as early as possible. (pubmed.ncbi.nlm.nih.gov)
No separate company press release or broad industry reaction was readily visible in search results, but the broader field has been moving toward more accessible cardiac testing. IDEXX, for example, recently announced expansion of its Catalyst platform into point-of-care NT-proBNP testing, underscoring commercial interest in bringing cardiac biomarkers closer to the exam room. That's not a direct response to this study, but it does suggest the market is actively evolving around the same clinical need: faster screening access without overpromising on what a biomarker alone can diagnose. (ir.idexx.com)
Why it matters: For general practitioners and cardiology-focused teams, this study is likely to reinforce a tiered approach. Point-of-care biomarkers may be useful for screening high-risk Dobermans, prioritizing referrals, or supporting conversations with pet parents when echo or Holter testing isn't immediately feasible. But if the published data confirm lower accuracy than lab-based cTnI, especially in early disease, clinics will need to be careful about false reassurance from normal in-house results and about overinterpreting abnormal results without confirmatory testing. In a breed where annual surveillance is already recommended, assay choice and test positioning inside the workflow may matter almost as much as whether biomarker testing is offered at all. (pubmed.ncbi.nlm.nih.gov)
The paper may also be useful operationally. If the final publication includes actionable cutoffs, stage-specific performance, and comparison metrics, practices could better define when an in-clinic assay is "good enough" for interim screening and when a send-out or specialist workup should be the default. That would be especially relevant for wellness screening in middle-aged Dobermans, breeding evaluations, and follow-up of dogs with equivocal prior findings. This is an inference from the study topic and existing screening guidance, but it's consistent with how biomarkers are already used in Doberman DCM pathways. (pubmed.ncbi.nlm.nih.gov)
What to watch: The next step is the full Frontiers publication. Veterinary readers will want the actual sensitivity, specificity, ROC data, and stage-level comparisons before changing protocols, particularly to see whether Vcheck's convenience offsets any loss in early-detection performance. (frontiersin.org)